Intranasal ciclesonide coadministration with inhaled fluticasone propionate-salmeterol does not suppress cortisol in allergic rhinitis patients.
نویسندگان
چکیده
Intranasal and inhaled corticosteroid administration concurrently in comorbid allergic rhinitis (AR) and asthma may potentially enhance cortisol suppression. This study determined whether intranasal ciclesonide 200 micro g once daily has an additional effect on cortisol suppression when coadministered with inhaled fluticasone propionate-salmeterol (FP-SAL) 500 to 50 micro g twice daily. Adults (N = 150) with perennial AR received FP-SAL and placebo nasal spray during the run-in period. Patients were randomized to ciclesonide or placebo and FP-SAL (43 days). A single 2-mg dose of dexamethasone was administered on the last treatment day. Plasma cortisol decreased during run-in period (p < 0.001), indicating cortisol suppression by FP-SAL. After ciclesonide was added to FP-SAL, plasma cortisol was similar in both groups. Dexamethasone decreased mean plasma cortisol (p < 0.001), demonstrating that further suppression was possible. Ciclesonide coadministered with FP-SAL did not have an additive effect on cortisol suppression compared with FP-SAL.
منابع مشابه
Adrenal suppression in an asthmatic presenting after change from high dose inhaled fluticasone propionate to inhaled budesonide
Case description A ten-year-old boy with asthma, peanut allergy, and allergic rhinitis had been maintained on a regimen of FP/salmeterol 500 mcg per day and mometasone furoate nasal spray 50 mcg per day. During exacerbations FP 500 mcg per day was added. He had no oral steroid usage. After a stable period with only FP/salmeterol, his regimen was changed to BUD/formoterol 800 mcg per day. Shortl...
متن کاملAzelastine nasal spray for the treatment of allergic and nonallergic rhinitis.
Rhinitis affects millions of people around the world, places a huge burden on the economy and reduces patients' health-related quality of life. Azelastine nasal spray is a second-generation antihistamine, indicated for the treatment of allergic and nonallergic rhinitis in both adults and children. It offers a rapid onset of action (15 min) and flexibility of both dose (i.e., one or two sprays/n...
متن کاملInhaled and intranasal fluticasone propionate and haematoma
Fluticasone propionate is a locally acting potent corticosteroid and is registered in the Netherlands since November 1990. It is marketed as nasal drops and nasal spray (Flixonase) for the indications vasomotor and allergic rhinitis, nasal polyps, and as inhalation corticosteroid (ICS) (Flixotide) in both an inhalation dosisaerosol and a powder inhalation form for indications asthma and chronic...
متن کامل24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids.
BACKGROUND As both rhinitis and asthma are allergic conditions, they frequently occur together. The objective of this study was to assess the diurnal adrenocortical activity in asthmatics receiving inhaled (inh) and intranasal (n) formulations of two different corticosteroids, fluticasone propionate (FP) and triamcinolone acetonide (TAA), both given at clinically recommended doses. METHODS Tw...
متن کاملFluticasone furoate nasal spray in the treatment of allergic rhinitis
Allergic rhinitis (AR) is a prevalent disease with great morbidity and significant societal and economic burden. Intranasal corticosteroids are recommended as first-line therapy for patients with moderate-to-severe disease, especially when nasal congestion is a major component of symptoms. To compare the efficacy and safety profile of different available intranasal corticosteroids for the treat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of asthma : official journal of the Association for the Care of Asthma
دوره 44 7 شماره
صفحات -
تاریخ انتشار 2007